ClinicalTrials.gg
CompletedNCT00548067Updated Sep 27, 2010

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

A Phase 3 interventional study of Valsartan/hydrochlorothiazide (HCTZ) and Valsartan/amlodipine in Hypertension, sponsored by Novartis. Completed at 5 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2010-09-27.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 123 studies testing hydrochlorothiazide in Hypertension — 2 open to participants now, 3 under way, none of them phase 3. Hydrochlorothiazide · Hypertension.

Enrollment
83rd of 121
111 · median 229
Started
2007
with 7 others
Phase 3
35 of 123
none open now
Registered
47th of 123
by date
Lead sponsor
33 of 123
Novartis

Among the 123 studies testing hydrochlorothiazide in Hypertension, this one is the 83rd largest by enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2007, is one of 35 in phase 3, and was the 47th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 123 studies testing hydrochlorothiazide in Hypertension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About hydrochlorothiazide

Hydrochlorothiazide: first FDA approval 1959 (ESIDRIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies testing hydrochlorothiazide in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High blood pressure, hypertension, drug interaction, steady state, valsartan, hydrochlorothiazide, amlodipine
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as hypertensive
  • Untreated confirmed hypertensive patients (consistent SBP >140 mm Hg or DBP >90 mm Hg)
  • Uncontrolled hypertensive patients (Consistent SBP >140 mm Hg or DBP >90 mm Hg) on one drug therapy.
  • Uncontrolled hypertensive patients (Consistent SBP >140 mm Hg or DBP >90 mm Hg) on two drug therapy.

Exclusion criteria

Exclusion Criteria:

  • Inability to switch from all prior antihypertensive medications safely as required by the protocol.
  • Need for drugs other than study drugs at the time of baseline.
  • Patients with SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg at screening.
  • Patients on four or more antihypertensive drugs at screening.
  • Pregnant or nursing (lactating) women.
  • Patients with diabetes mellitus
  • Patients with heart diseases and any other disease

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Valsartan/hydrochlorothiazide (HCTZ)

  • Active comparator
    2

    Drug: Valsartan/amlodipine

  • Active comparator
    3

    Drug: Amlodipine/hydrochlorothiazide(HCTZ)

  • Experimental
    4

    Drug: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)

Interventions

06

What researchers measure

Primary outcomes

  1. Potential drug interaction and effect on blood level of drugs when co-administered for 17 days

Secondary outcomes

  1. Safety and tolerability of co-administered assessed by capturing adverse events and safety laboratory

07

Study locations

5 sites
  • Novartis Investigative Site
    Ahmedabad, India
  • Novartis investigative site
    Bangalore, India
  • Novartis Investigative site
    Hyderabad, India
  • Novartis Investigative site
    Mangalore, India
  • Novartis investigative site
    Mehasana, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2007
First posted
Oct 23, 2007
Start
Sep 2007
CompletionActual
Mar 2008
Last update
Sep 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00548067
Lead sponsor
Novartis
First posted
Oct 23, 2007
Start date
Sep 2007
Completion
Mar 2008
Last update
Sep 27, 2010

Study contacts

Novartis
principal investigator · Novartis investigative site

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydrochlorothiazide · Valsartan · Amlodipine

Start the discussion